Skip to main content

Table 4 Factor for correction of indirect (herd) effects

From: Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany

Age group   IPD CAP
15 - 39   37,4%* 23.6%*
40 - 44   39.7%* 23.6%*
45 - 49   39.7%* 16,2%*
50 - 64   17.5%* 16,2%*
65+   37.9%* 14.3%*
  1. *Adjusted according to Claes et al. for German serotype coverage based on IPD data from Pilishvili et al. and CAP data from Ray et al. [34].